| Medical and Health Sciences | 2021-2025 | 185 | US 70 | 99.96 |
| Cardiology and Cardiovascular Medicine | Lifetime | 486 | US 267 | 99.28 |
| Nutrition and Dietetics | Lifetime | 517 | US 214 | 97.71 |
| Endocrine and Autonomic Systems | Lifetime | 968 | US 484 | 70.12 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 52 | US 32 | 99.80 |
| Public, Environmental and Occupational Health | 2021-2025 | 219 | US 85 | 98.11 |
| Surgery | 2021-2025 | 404 | US 158 | 96.98 |
| Nutrition and Dietetics | 2021-2025 | 158 | US 32 | 95.40 |
| Organizational Behavior and Human Resource Management | 2021-2025 | 248 | US 51 | 94.15 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 451 | US 177 | 86.77 |
| Blood Pressure and Hypertension Studies | Lifetime | 177 | US 80 | 99.40 |
| Cardiovascular Health and Disease Prevention | Lifetime | 179 | US 86 | 98.97 |
| Hemodynamic Monitoring and Therapy | Lifetime | 166 | US 61 | 98.68 |
| Sodium Intake and Health | Lifetime | 79 | US 38 | 98.55 |
| Heart Rate Variability and Autonomic Control | Lifetime | 712 | US 323 | 97.82 |
| Global Public Health Policies and Epidemiology | Lifetime | 222 | US 60 | 97.28 |
| Nutritional Studies and Diet | Lifetime | 629 | US 249 | 97.99 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 621 | US 257 | 97.46 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 850 | US 347 | 97.34 |
| Cardiovascular Health and Risk Factors | Lifetime | 388 | US 225 | 95.22 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 674 | US 164 | 88.50 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 4 | US 2 | 99.83 |
| Hemodynamic Monitoring and Therapy | 2021-2025 | 4 | US 2 | 99.66 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 12 | US 4 | 99.39 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 14 | US 3 | 98.91 |
| Sodium Intake and Health | 2021-2025 | 7 | US 3 | 99.07 |
| Non-Invasive Vital Sign Monitoring | 2021-2025 | 69 | US 16 | 96.46 |
| Nutritional Studies and Diet | 2021-2025 | 174 | US 42 | 97.34 |
| Hormonal Regulation and Hypertension | 2021-2025 | 89 | US 27 | 96.16 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 166 | US 90 | 92.79 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 236 | US 43 | 89.68 |
| Cardiovascular and exercise physiology | 2021-2025 | 359 | US 63 | 93.11 |
| Climate Change and Health Impacts | 2021-2025 | 625 | US 152 | 91.15 |
| Pharmaceutical Economics and Policy | 2021-2025 | 855 | US 276 | 72.11 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 743 | US 227 | 68.95 |
| Renal function and acid-base balance | 2021-2025 | 879 | US 242 | 50.07 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 795 | US 133 | 49.51 |
| Renin-Angiotensin System Studies | 2021-2025 | 678 | US 216 | 40.41 |
| Apelin-related biomedical research | 2021-2025 | 658 | US 103 | 37.93 |
| Pharmaceutical industry and healthcare | 2021-2025 | 681 | US 369 | 26.57 |